Tech Company Financing Transactions
OphthoTech Funding Round
OphthoTech, based in New York, scored $175 million in investment from Novo Ventures and private investors.
Transaction Overview
Company Name
Announced On
5/29/2013
Transaction Type
Venture Equity
Amount
$175,000,000
Round
Undisclosed
Investors
Novo Ventures (Lead Investor)
Proceeds Purpose
The financing of $175 million consists of $125 million from Novo A/S, in exchange for royalties on Fovista sales. The remaining $50 million is in the form of a Series C preferred stock financing from Novo A/S and current venture investors in Ophthotech. The royalty and Series C funding is structured in three equal tranches, the first of which has closed.
Company Information
Company Status
Publicly-held
Industry
Biopharmaceutical
Mailing Address
1 Penn Plz. 3520
New York, NY 10119
USA
New York, NY 10119
USA
Phone
Website
Email Address
Overview
Ophthotech Corporation (NASDAQ: OPHT) is a biopharmaceutical company focusing on discovering, developing and commercializing first-in-class therapies for the treatment of major ophthalmic diseases.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Glenn Sblendorio
Chief Financial Officer
David Carroll
Chief Medical Officer
Kourous Rezaei
Chief Operating Officer
Evelyn Harrison
Chief Operating Officer
Keith Westby
VP - General Counsel
Todd Anderman
VP - Human Resources
Amy Sheehan
Browse more venture capital transactions:
Prev: 5/28/2013: Appurify venture capital transaction
Next: 5/29/2013: DoYouRemember venture capital transaction
Share this article
News on VC Transactions
We do our best to report on every notable VC transaction. VC investment data records reported here are derived from a variety of public sources. The information is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs